Ignite Creation Date:
2025-12-24 @ 2:23 PM
Ignite Modification Date:
2026-01-18 @ 1:20 PM
Study NCT ID:
NCT07209059
Status:
RECRUITING
Last Update Posted:
2025-10-06
First Post:
2025-07-03
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
Sponsor:
National Research Center for Hematology, Russia
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Classical Hodgkin Lymphoma | View |
| None | Hodgkin Disease | View |
| None | Nivolumab | View |
| None | Immunotherapy | View |
| None | First-line treatment | View |
| None | PET-adapted therapy | View |
| None | Checkpoint inhibitors | View |
| None | ctDNA | View |
| None | Response-adapted treatment | View |
| None | EACOPD | View |
| None | AVD | View |
| None | PD-1 blockade | View |
| None | Circulating tumor DNA | View |